1205-50-1

Usage

InChI:InChI=1/C9H9ClO4/c1-13-7-4-5(9(12)14-2)3-6(10)8(7)11/h3-4,11H,1-2H3

Upstream product

• 62936-23-6 3-chloro-4-hydroxy-5-methoxybenzoic acid 
• 67-56-1 methanol 

Downstream Products

• 1026155-80-5 3-Chloro-4-hexyloxy-5-methoxy-benzoic acid methyl ester 
• 1026271-46-4 3-Chloro-4-hexyloxy-5-methoxy-benzoyl chloride 
• 904688-12-6 3-Chloro-4-hexyloxy-5-methoxy-benzoic acid 
• 1026957-82-3 3-Chloro-4-hexyloxy-5-methoxy-benzoic acid 4-chloro-butyl ester 
• 712294-48-9 3-chloro-4-ethoxy-5-methoxybenzoic acid 
• 1160755-55-4 3-chloro-5-methoxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoic acid methyl ester 

Relevant academic research and scientific papers

Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist

A ligand-based virtual screening exercise examining likely bioactive conformations of AM 580 (2) and AGN 193836 (3) was used to identify the novel, less lipophilic RARα agonist 4-(3,5-dichloro-4-ethoxybenzamido)benzoic acid 5, which has good selectivity over the RARβ and RARγ receptors. Analysis of the medicinal chemistry parameters of the 3,5-substituents of derivatives of template 5 enabled us to design a class of drug-like molecules with lower intrinsic clearance and higher oral bioavailability which led to the novel RARα agonist 4-(3-chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid 56 that has high RARα potency and excellent selectivity versus RARβ (2 orders of magnitude) and RARγ (4 orders of magnitude) at both the human and mouse RAR receptors with improved drug-like properties. This RARα specific agonist 56 has high oral bioavailability (>80%) in both mice and dogs with a good PK profile and was shown to be inactive in cytotoxicity and genotoxicity screens.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.